---
layout: post
title: "Prospective Grant of Exclusive Patent License: Development and Commercialization of Regulatory T-Cell Therapies for the Treatment of Multiple Sclerosis (MS)"
date: 2026-02-05 18:57:50 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-01330
original_published: 2022-01-25 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of Exclusive Patent License: Development and Commercialization of Regulatory T-Cell Therapies for the Treatment of Multiple Sclerosis (MS)

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** January 25, 2022 00:00 UTC
**Document Number:** 2022-01330

## Summary

The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this notice to TeraImmune, Inc. ("TeraImmune") located in Gaithersburg, Maryland, USA.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/01/25/2022-01330/prospective-grant-of-exclusive-patent-license-development-and-commercialization-of-regulatory-t-cell)
- API: https://www.federalregister.gov/api/v1/documents/2022-01330

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
